Abstract:Objectives: CD25 (IL-2Rα) is one of IL-2 receptor's polypeptide subunits, and its soluble form is increased in patients with various inflammatory or autoimmune diseases. This study aimed to evaluate the clinical correlation of serum soluble CD25 (sCD25) with interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. Methods: 294 RA patients, including 72 in the discovery cohort (15 patients with ILD, 57 patients without ILD), 222 in the validation cohort (41 patients with ILD and 181 patients without ILD), and 58 healthy controls (HCs) were recruited. High-resolution computed tomography (HRCT) scan provided evidence and patterns of RA-ILD. Serum sCD25 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Clinical and laboratory data were recorded and the association with sCD25 was also analysed. Results: In the discovery cohort, 16 RA-related molecules including cytokines, chemokines and functional soluble cell surface proteins were investigated. The results showed that sCD25 was significantly higher in RA-ILD than in RA-no-ILD group (p=0.004). ROC analysis also showed RA-ILD was discriminated with RA-no-ILD by sCD25 (AUC=0.695, 95% CI=0.541-0.849). Logistics regression demonstrated that sCD25 was one of the risk factors of RA-ILD. This result was further confirmed in validation cohort (p<0.001). According to the cut-off value in the discovery cohort, the sensitivity and specificity of sCD25 in RA-ILD were 51.2%, 77.3%, respectively. Compared with RA-no-ILD, serum level of sCD25 was also higher in different HRCT patterns including UIP, NSIP and RA-ILA. The ROC curves revealed sCD25 as diagnostic marker in UIP, NSIP and RA-ILA (with AUCs of 0.730, 0.761, and 0. 694, respectively, p<0.05). The result indicated that sCD25 was a biomarker for RA-ILD subtypes. Although sCD25 was not correlated with HRCT scores, it was significantly higher in consolidation pattern by HRCT. Conclusions: sCD25 was significantly elevated in RA-ILD (including UIP, NSIP and RA-ILA) compared to RA-no-ILD and HCs, which supports their value as a potential biomarker in RA-ILD screening and assessment.

Serum level of carbohydrate antigen 15-3 in patients with interstitial lung diseases and its correlation with pulmonary function and high-resolution computed tomography

Serum CA 125 Level in Patients with Acute Pulmonary Thromboembolism

CA 15 - 3 in screening for systemic autoimmune rheumatic disease associated interstitial lung disease: a single center cross-sectional study

Elevated Carcinoembryonic Antigen Predicts Rapidly Progressive Interstitial Lung Disease in Clinically Amyopathic Dermatomyositis

Identification of serum interleukin-13 and interleukin-13 receptor subunit expressions: Rheumatoid arthritis-associated interstitial lung disease

The Characteristics and Clinical Significance of Mucin Levels in Bronchoalveolar Lavage Fluid of Patients with Interstitial Lung Disease.

Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis

Study on the correlationship between CK19mRNA and CyFRA21-1 in peripheral blood of lung cancer patients

CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia

Association of serum tumor markers with interstitial lung disease in patients with or without connective tissue disease: A cross-sectional study

Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease

Serum CA153 as biomarker for cancer and noncancer diseases

Assessing the diagnostic utility of serum tumor markers for lung cancer detection in patients with interstitial pneumonia

Diagnostic performance of specific biomarkers for interstitial lung disease: a single center study

Clinical significance of tumor markers in idiopathic pulmonary fibrosis

Krebs Von Den Lungen-6 Associated with Chest High-Resolution CT Score in Evaluation Severity of Patients with Interstitial Lung Disease.

Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis

Expression and clinical significance of biomarkers in serum and bronchoalveolar lavage fluid from patients with connective tissue disease-associated interstitial lung disease

Serum Oncomarkers in Patients with MPO-ANCA-Positive Vasculitis: Diagnostic and Prognostic Predictive Values for Interstitial Lung Disease

Elevated Serum Levels Of Mucin-Associated Antigen In Patients With Acute Respiratory Distress Syndrome

Patterns of Interstitial Lung Disease in Egyptian Patients with Systemic Sclerosis: Relation to Disease Parameters